ARDX
Ardelyx, Inc.
Ardelyx (ARDX) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- Revenue $118M, up 31% from $90.1M a year ago.
- GAAP EPS −$0.07, up from −$0.08 a year ago.
- Ardelyx reported total product revenue of $118.1 million for the second quarter, a 31% increase year-over-year.
- IBSRELA revenue grew 33% to $86.2 million, while XPHOZAH revenue rose 27% to $31.9 million.
- The company narrowed its net loss to $16.7 million, or $0.07 per share, compared to $19.1 million a year ago.
Results vs analyst consensus
Revenue
Reported
$118M
Consensus not captured before release
+31% YoY
EPS · GAAP
Reported · GAAP diluted EPS
−$0.07
Consensus not captured before release
Prior year: −$0.08
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Increased utilization management processes from payors are negatively impacting IBSRELA revenue growth.
- The company pulled its long-term revenue guidance for XPHOZAH due to evolving market dynamics.
Read original report
Source: Ardelyx, Inc. press release · SEC Form 8-K exhibit 99.1